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Abstract
Sporadic pancreatic cancer (SPC) has been frequently associated with impaired glucose 
homeostasis manifested by prediabetes, Type 2 diabetes or predominantly by T3c diabetes 
which develops as the first symptom of cancer. Pathogenic mechanisms in the development 
of T3c diabetes have not been fully elucidated although specific substances originating in 
the tumor cells are supposed to be the cause of β-cell dysfunction and insulin resistance. 
New biomarkers evaluated in patients with recent-onset diabetes are necessary for the early 
diagnosis of this tumor. Actual data characterizing risk factors, early symptoms, patho-
genic mechanisms, biomarkers and structured programs in detection of SPC are described. 
A multidisciplinary team of primary care physicians, gastroenterologists, endoscopists, 
radiologists and pathologists should improve the prognosis of this malignant disease.
Keywords: sporadic pancreatic cancer, risk factors, early symptoms, T3c diabetes 
mellitus, β-cell dysfunction, insulin resistance, biomarkers, multidisciplinary team 
approach
1. Introduction
Pancreatic adenocarcinoma is a highly malignant cancer which occurs in three different forms: 
(1) sporadic pancreatic cancer (SPC) accounting for 90% of all pancreatic cancers, (2) familial 
pancreatic cancer accounting for 7%, and (3) pancreatic cancer as a part of genetic cancer 
syndromes, which account for the remaining 3%. A detailed program of long-term tertiary 
prevention (surveillance) is available for the two smaller groups. In contrast, there has been, 
up to now, no preventive program for the much larger SPC group.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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The clinical diagnostics of SPC starts now much as it did in the middle of the past century, 
that is, after the appearance of local and/or systemic symptoms. They include abdominal and 
back pain, fatigue, loss of body weight, painless jaundice, anemia, peripheral phlebitis, and 
cachexia. These symptoms are nevertheless also harbingers of advanced disease.
High-resolution imaging methods (HRIMs: CT, MRI, MRCP, EUS) and histomorphology pro-
vide information suitable for diagnostics; nevertheless, their impact on patient prognosis is 
limited as they are typically ordered at an advanced disease stage. Radical surgery may only 
be suitable for 15–20% of patients. The relapses are frequent as well as early, and chemother-
apy is basically palliative. This confluence of factors results in very low 5-year survival rates 
of only 3–6% of patients [1].
We recently recommended a screening program for early SPC detection based on cooperation 
of primary care physicians with gastroenterologists and other specialists [2].
2. Sporadic pancreatic cancer development
Pancreatic carcinogenesis begins with the transformation of pancreatic cells and evolution of 
the precancerous lesions (precursors). At present, six precursors with different morphologies 
and malignant potential are distinguished [serous microcystic adenoma (SMA); intraductal 
papillary mucinous neoplasm (IPMN); intraductal tubulopapillary neoplasm (ITPN); muci-
nous cystic neoplasm (MCN); pancreatic intraepithelial neoplasm (PanIN); and solid pseudo-
papillary neoplasm (SPN)] [3, 4]. The development of SPC based on the gradual accumulation 
of genetic and epigenetic alterations consists of three stages: (1) time prior to the invasive 
lesion, (2) time to the development of the metastatic subclone, and (3) time period of meta-
static dissemination that leads to patient death. The average duration of the first two time 
periods is estimated to be about 18 years. Early detection must be concentrated during these 
two periods, when patients are often without any symptoms [5].
3. Sporadic pancreatic cancer and diabetes mellitus
The association between diabetes mellitus and pancreatic cancer has been repeatedly 
observed, and several case–control and cohort studies have been analyzed in meta-analyses 
[6]. The relationship between diabetes and SPC is reciprocal. While long-term diabetes is con-
sidered an etiologic/risk factor of SPC, new-onset diabetes may be the first manifestation of 
SPC [7] as recently summarized by D.K. Andersen [8].
3.1. Type 2 diabetes and obesity: important risk factors
Long-term Type 2 diabetes is a risk factor of SPC with a latency of more than 5 years, and an 
incidence that is approximately doubled [9, 10]. However, Type 2 diabetes develops from 
prediabetes and is frequently symptom-free for several years without clinical manifesta-
tions, which allows it to go undiagnosed. Exposure to the protumorgenic effects of Type 2 
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 diabetes is in reality often longer than would be expected based on the time point at which 
the diagnosis was established. Hyperglycemia is the main factor inducing a cluster of events 
like higher oxidative stress, formation of advanced glycation end products, and inflamma-
tion. Such changes increase proliferation, invasiveness, and metastatic potential of pancreatic 
cancer [11]. Stimulation of receptors for advanced glycation end products (RAGE) promotes 
pancreatic cancer development, whereas their inhibition was reported to have opposite effects 
[12, 13]. Hyperinsulinemia exists in prediabetes and in the initial phase of Type 2 diabetes as 
a consequence of obesity and insulin resistance. Higher intrapancreatic insulin concentrations 
may stimulate proliferation of pancreatic tumor cells by activating insulin-like growth factor 
receptors (IGF-1R) and the downstream PI3K/Akt/mTOR signaling pathway [14].
Long-term Type 2 diabetes is frequently associated with obesity, which by itself is another 
independent factor increasing the risk of pancreatic cancer development. Fat tissue as an endo-
crine organ produces and secretes hormones (adipokines) including leptin and adiponectin, 
which have been linked to cancer development. The key signaling pathway linking obesity 
and cancer is the PI3K/Akt/mTOR cascade which regulates cell proliferation and survival [15]. 
Leptin is positively correlated with adipose stores and nutritional status. It induces cancer 
progression by activating the PI3K, MAPK, and STAT3 signaling pathways [16]. In contrast 
to leptin, adiponectin is inversely associated with adiposity, hyperinsulinemia, and inflam-
mation. It exhibits anticancer effects by decreasing insulin/insulin-like growth factor (IGF-1) 
and mTOR signaling via activation of 5′AMP-activated protein kinase (AMPK) and exert-
ing anti-inflammatory actions via the inhibition of the nuclear kappa-light-chain enhancer 
of activated B-cells (NF-κB) [17]. Activation of NF-κB complex by stimulated RAGE is a pos-
sible mechanism through which inflammation may stimulate pancreatic cancer development 
[18]. In addition, obesity is frequently associated with hyperinsulinemia and may therefore 
through complex mechanism increase the risk of pancreatic cancer.
3.2. New-onset T3c diabetes: an early symptom of sporadic pancreatic cancer
Newly developed impairment of glucose homeostasis represented either by prediabetes 
(impaired fasting glucose or impaired glucose tolerance) or diabetes develops as the sole early 
symptom of SPC and is called pancreatogenic diabetes Type 3c (T3cDM), which appears up 
to 24 months (or even 36 months according to some investigators) before the clinical manifes-
tation of SPC [19–21]. The relative probability of an already existing undiagnosed SPC is the 
highest in patients who were diagnosed with impairment of glucose homeostasis within the 
last 12 months (RR 5.4: 95% CI 3.5–8.3) [22]. A causal relationship between SPC and T3c diabe-
tes is supported by the observation that diabetes resolves after surgical removal of the tumor in 
more than 50% of patients [23]. However, improvement of glucose homeostasis may be linked 
to the surgical procedure itself since it has also been demonstrated that subtotal pancreato-
duodenectomy similarly improved diabetes in patients with or without pancreatic cancer [24].
T3c diabetes, which represents up to 8% of the total number of patients with diabetes mellitus, 
can occur secondary to other pancreatic disorders like chronic pancreatitis, hemochromatosis, 
or cystic fibrosis; however, in these cases, clinical manifestation of exocrine insufficiency usu-
ally precedes the development of pancreatic endocrine dysfunction [25]. Pancreatic cancers 
occur in about 9% of patients with T3cDM [26]. Therefore, one case of SPC per roughly 140 
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patients with new-onset diabetes can be expected. Patients with new-onset diabetes are asso-
ciated with a 4- to 7-fold increase in risk of pancreatic cancer, such that 1–2% of patients with 
recent-onset diabetes were suggested to develop pancreatic cancer within 3 years [27].
4. Pathophysiology of T3cDM associated with sporadic pancreatic 
cancer
The pathophysiological relationship between T3cDM and SPC remains largely unknown. The 
high proportion of patients who develop T3cDM as the first clinical symptom of SPC (about 
74% patients developing diabetes up to 24 months prior to SPC diagnosis) suggests that the 
tumor is the cause of the diabetes [28]. In addition, the prevalence of diabetes in patients with 
SPC is much higher (68%) compared to diabetes that develops in association with other can-
cers (up to 24%) [29].
4.1. β-cell dysfunction and insulin resistance
New-onset diabetes associated with SPC is a paraneoplastic phenomenon that is charac-
terized by impaired insulin secretion and insulin resistance [30]. Impaired glucoregulation 
develops gradually. Approximately 15–20% SPC patients are normoglycemic with normal 
β-cell function but increased insulin resistance. Subjects with impaired glucose tolerance have 
disturbed β-cell function, but the insulin resistance is not significantly different from the pre-
ceding group. The changes in β-cells associated with SPC are initially functional as previously 
supposed in experimental study [31]. In contrast, morphological changes or a decrease of 
their counts are associated with other diseases of the exocrine pancreas, that is, chronic pan-
creatitis, cystic fibrosis, tropical pancreatitis, and hemochromatosis [32].
Several findings support the hypothesis that β-cell dysfunction is caused by substances over-
produced by the cancer cells [21], which may impair glucose-stimulated insulin release and 
contribute to glucose dysregulation. Macrophage migration inhibitory factor (MIF) is a pro-
inflammatory cytokine which affects both inflammation and glucose homeostasis. Its over-
production by pancreatic cancer cells has been observed, and its effect on the inhibition of 
glucose-stimulated insulin release from β-cells as well as from isolated islets, through regula-
tion of Ca2+ channels, has also been demonstrated [33]. In addition, increased serum levels 
of MIF have been found in new-onset diabetic patients with pancreatic cancer while no such 
increase has been seen in patients with pancreatic cancer without diabetes or in non-cancer 
new-onset Type 2 diabetic patients [33]. Cancer cells have also been shown to upregulate 
adrenomedullin, a potent inhibitor of insulin secretion (see below) [34, 35].
In addition to β-cell dysfunction, a significant increase in insulin resistance develops in SPC 
patients with diabetes [36]. Peripheral insulin resistance was confirmed by hyperinsulinemic 
clamps in patients with pancreatic cancer and was found to be higher in those with diabetes 
than in nondiabetic subjects [37]. Improved insulin sensitivity was observed after  surgical 
removal of the pancreatic cancer [37]. Insulin resistance was found to be associated with 
reduced glycogen synthesis in muscles, which was also confirmed in vitro [37]. Impaired gly-
cogen synthesis and glycogen storage in muscles were caused by defects at the post-receptor 
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level [38]. No changes in receptor tyrosine kinase activity, insulin-receptor substrate (IRS-1), 
or glucose transporter GLUT-4 were found in skeletal muscle biopsies of pancreatic cancer 
patients as compared to healthy controls [38]. Muscle insulin resistance was also unrelated to 
weight loss, plasma free fatty acids, or the energy status of cells and medium conditioned by 
pancreatic cancer cells did not induce insulin resistance in muscle cells in vitro [39]. Hepatic 
insulin resistance as determined by HOMA-IR indexes was observed in patients with pan-
creatic cancer [36]. Hepatic insulin resistance seems to be caused by pancreatic polypeptide 
deficiency and administration of pancreatic polypeptide has the potential to improve insulin 
sensitivity in the liver [40, 41]. In addition, adrenomedullin and tumor-derived exosomes may 
significantly contribute to the development of insulin resistance in SPC patients (see below).
4.1.1. Adrenomedullin
Adrenomedullin secreted by pancreatic cancer cells was found to be an important factor influ-
encing β-cell function. It was first identified in 1993 in a pheochromocytoma as a hypoten-
sive peptide [42]. It binds with three types of specific receptors (ADMR), which belong to 
the 7-transmembrane superfamily of G-protein-coupled receptors. One of them, the calcito-
nin receptor-like receptor (CRLR), is modulated by the receptor activity modifying protein 
(RAMP) [43]. Adrenomedullin is released by pancreatic cancer cells in exosomes. These mem-
brane-bound vesicles contain proteins, miRNAs, and other molecules and traffic molecular 
cargo from the cell-of-origin to target sites in the body. After endocytosis or macro-pinocy-
tosis of adrenomedullin-containing exosomes, adrenomedullin binds to its receptors, initi-
ates endoplasmic reticulum (ER) stress and consequently the intracellular increase of reactive 
oxygen/nitrogen species (ROS/RNS) that can lead to β-cell dysfunction and death [30]. These 
observations provide new insights into the relationship between pancreatic cancer and new-
onset diabetes. The SPC-associated diabetes was therefore proposed to be an example of an 
“exosomopathy,” a novel exosome-based disease mechanism [44].
Body weight loss is another symptom frequently accompanying new-onset diabetes associ-
ated with SPC. It usually starts shortly after the onset of diabetes, precedes the develop-
ment of other symptoms, and progresses up to the diagnosis of SPC. Weight loss varies 
extensively among individual patients with an average loss of between 4 and 5 kg. Weight 
loss may have a similar paraneoplastic origin as T3cDM. The adrenomedullin-containing 
exosomes secreted from pancreatic cancer cells interact with adipose cells and are internal-
ized by endocytosis. Adrenomedullin via its receptors activates p38 and ERK1/2 MAPKs and 
promotes lipolysis through phosphorylation of hormone sensitive lipase [45]; thus, the loss 
of subcutaneous fat observed in SPC may be a paraneoplastic symptom mediated by exo-
somal adrenomedullin. Exosome induced β-cell dysfunction and lipolysis could be inhibited 
by adrenomedullin receptor blockade [30, 45], which underscores the role of adrenomedullin 
in the development of new-onset diabetes and weight loss in SPC. Nevertheless, exosomes 
are involved in several other aspects of cancer development including angiogenesis, stro-
mal remodeling, chemo-resistance, and genetic intercellular exchange [46]. Cancer-derived 
exosomes can also enter muscle cells and inhibit insulin and PI3K/Akt signaling, leading to 
impaired GLUT 4 trafficking [47]. This effect leading to skeletal muscle insulin resistance 
may be mediated by microRNAs carried by exosomes [47]. This interaction between pancre-
atic cancer cells and normal cells represents another example of a “metabolic crosstalk” in 
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malignant tumors [47]. In additional to the peripheral insulin resistance expressed in skel-
etal muscles, impaired insulin action has been found in the liver where similar pathogenic 
mechanisms may be present [32].
4.1.2. Dipeptidyl peptidase 4 and fibroblast activation protein alpha
The membrane-bound proteases dipeptidyl peptidase 4 (DPP4, EC 3.4.14.5, CD26) and fibro-
blast activation protein alpha (FAP alpha, EC 3.4.21.B28, seprase) may represent other fac-
tors contributing to impaired glucoregulation in SPC [48]. DPP4 is a membrane glycoprotein 
expressed on the surface of many cell types including endothelial and epithelial cells, fibro-
blasts, and activated lymphocytes. Its soluble form is also present in the serum and other 
body fluids. FAP alpha is a close structural homolog of DPP4 with 52% amino acid sequence 
identity. Under physiological conditions, the expression of FAP alpha is restricted to alpha 
cells of pancreatic islets and stromal cells in the uterus. During carcinogenesis, FAP alpha 
is upregulated in the stromal fibroblasts of various malignancies [49]. FAP alpha positive 
fibroblasts have been found in primary and secondary cancerous lesions, whereas benign 
epithelial lesions rarely contain FAP alpha positive stromal cells.
DPP4 and FAP alpha are multifunctional proteins that exhibit both enzyme activity depen-
dent and enzyme activity independent biological functions. The catalytic activity of DPP4 and 
FAP alpha cleaves off the N-terminal dipeptide from peptides and proteins containing proline 
or alanine in the penultimate position. In addition, FAP alpha also possesses endopeptidase 
enzymatic activity, with the potential to cleave among others FGF21 [49]. A number of DPP4 
and FAP alpha substrates are related to the regulation of glucose metabolism and energy 
homeostasis (Table 1). The proteolytic cleavage significantly modifies the biological activity 
of the targets leading to inactivation, modified receptor preference, or increased susceptibility 
to cleavage by other proteases [50].
Biopeptide Main physiological functions References
GIP* Stimulation of insulin and glucagon secretion [78]
GLP-1* Stimulation of glucose-stimulated insulin secretion, inhibition of glucagon 
secretion
[78]
PYY*,**
NPY*,**
Regulation of food intake, adipogenesis, energy homeostasis, glucose-stimulated 
insulin secretion, lipolysis and blood pressure. Involved in stress reaction and 
pain perception
[78–81]
Glucagon* Increase of glycemia and ketogenesis [79, 82, 83]
FGF21*,** Stimulation of glucose uptake in adipocytes, increase of energy expenditure [84–86]
VIP*, PACAP* Regulation of insulin and glucagon secretion, regulation of body weight, energy 
and lipid metabolism. Gastrointestinal motility. Immunomodulation
[87, 88]
GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide 1; PYY – peptide YY; NPY, neuropeptide 
Y; FGF21, fibroblast growth factor 21; VIP, vasoactive intestinal peptide; PACAP, pituitary adenylate cyclase-activating 
peptide.
Table 1. Biopeptides involved in glucose and energy homeostasis that are cleaved by DPP4* and/or FAP**.
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The role of DPP4 and FAP alpha has been studied in the context of various malignancies, 
including pancreatic cancer. Expression of both proteases is increased in SPC tissues and SPC 
patients with recent onset diabetes or prediabetes have increased plasma DPP4 enzymatic 
activity [51]. Increased expression and activity of these proteases may thus lead to decreased 
bioavailability of their substrates and thus contribute to impaired glucose homeostasis in SPC.
In summary, pancreatic cancer cells dysregulate the production of various substances with 
hormonal or enzymatic activities, which lead to impaired functioning of both the endocrine 
pancreas and other organs. New-onset T3cDM is therefore a consequence of impaired glucose 
homeostasis caused by the cancer cells.
5. Diagnosis of T3cDM
Early diagnosis of impaired glucose homeostasis is the first important step in the proper diag-
nosis of T3cDM associated with SPC. At this stage, the patient is usually without any clinical 
symptoms and a small decrease in body weight is frequently overlooked or considered unre-
lated. Determination of blood glucose every 2 years in patients over 50 years is highly recom-
mended as a part of regular preventive examinations by general practitioners. A finding of 
impaired fasting glucose (IFG) or increased random blood glucose should initiate the next 
level of examination (i.e., oral glucose tolerance test or HbA1c), which can confirm a diagnosis 
of prediabetes or diabetes.
The main task for physicians is to distinguish T3c diabetes from the more common Type 2 
or Type 1 diabetes, since in general practice only the latter two types are usually considered 
without any suspicion of T3c. Several indicators can be used for a better evaluation. Firstly, 
changes in body weight differ in subjects with T2DM vs. T3cDM after the appearance of dia-
betes. A decrease in body weight at the diagnosis of prediabetes or diabetes is significantly 
more frequent in patients with T3cDM than with T2DM, likely due to the tumor induced 
loss of subcutaneous fat tissue [45]. In SPC, the decrease in body weight usually precedes 
other systemic and local symptoms. T2DM frequently begins with increased body weight 
associated with insulin resistance and hyperinsulinemia and BMI is often higher compared 
to T3cDM [8]. A family history of diabetes is common in T2DM but not in T3cDM associated 
with SPC. The absence of markers of autoimmune disease may help exclude Type 1 diabetes. 
Therefore, an association of newly diagnosed prediabetes or diabetes with progressive weight 
loss should lead to the suspicion of T3cDM. Basic laboratory and clinical data that differenti-
ates T2DM and T3cDM are presented in Table 2.
The plasma pancreatic polypeptide (PP) concentration in the fasting state and after meal-stim-
ulation may also help discriminate between T2DM and T3cDM [8, 52]. The test is based on 
increased PP secretion after 30 min of nutritional stimulation in healthy controls and T2DM 
patients (usually by more than 100% of the baseline value); this increase is missing in T3cDM 
patients. The discriminative value of this test was found to be higher in cancer of the pancre-
atic head than in the other regions of the gland [53], since PP-cells are predominantly located 
within the head of the pancreas.
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6. Diagnosis of sporadic pancreatic cancer
Failure to diagnose SPC at an early stage is the main impediment to improving the prog-
nosis of patients with this malignant disease. Currently, more than 80% of cases are diag-
nosed in advanced stages (T3 and T4), which generally excludes radical surgery, the only 
possibly curative treatment. The prerequisite for early diagnosis of SPC is the timely use of 
high-resolution imaging methods (HRIMs), which will lead to the identification of patients 
with early stage, effectively curable disease. The specificity and sensitivity of the classical 
tumor biomarkers currently used in the clinical practice is low. Therefore, novel biomarkers 
are critically needed to identify patients in whom HRIMs should be used. Recently, we have 
proposed a structured diagnostic strategy for individuals with newly diagnosed diabetes, 
who represent a significant risk group for SPC, involving primary care physicians (both gen-
eral practitioners and diabetologists) [2].
6.1. Biomarkers
T3cDM with weight loss are alarming signs of a paraneoplastic origin and patients presenting 
with these signs require further examination. Recent reviews have summarized the present 
knowledge of biomarkers for the diagnosis of SPC [54–56]. A widely used biomarker, carbo-
hydrate antigen CA 19–9, is neither sufficiently specific (68–91%) nor sensitive (70–90%) in 
patients with SPC and, as such, it is not a reliable marker for screening and early detection 
[57]. While a more sensitive assay for CA 19–9 has been developed, which also demonstrated 
higher specificity [58], a combination of different markers in multiplex detection appears to 
be more promising. A biomarker panel consisting of three proteins: (1) plasma tissue factor 
pathway inhibitor (TFPI), (2) Tenascin-C (TNC-FN III-C), and (3) CA 19–9, was better than CA 
19–9 alone in early-stage cohorts (stage I and IIA/IIB), including the ability to  discriminate 
Indicator Type 2 DM Type 3c DM
Body weight Increase Decrease
Family history of DM Positive Frequently negative
Fasting plasma concentration
 Insulin High or normal Low or normal
 PP High or normal Low or normal
 GIP Normal Low or normal
Poststimulation levels
 Insulin High or normal Low
 PP High or normal Low
 GIP Normal Low
PP, pancreatic polypeptide; GIP, glucose-dependent insulinotropic peptide.
Table 2. Clinical and laboratory characteristics differentiating new-onset Type 2 from Type 3c diabetes associated 
with SPC.
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stage IA/IB/IIA from healthy controls [59]. This panel had the predictive power to detect 
early-stage pancreatic cancer and may have clinical utility for early detection of surgically 
resectable pancreatic ductal adenocarcinoma. In another study, a surface enhanced Raman 
spectroscopy (SERS) based immunoassay of CA 19–9 in combination with matrix metallo-
proteinase (MMP7) and mucin (MUC4) in serum had significantly enhanced sensitivity and 
could be a promising tool for liquid biopsy diagnostics [60].
MicroRNAs, small non-coding molecules circulating in blood, have been tested in patients 
with pancreatic cancer and healthy controls. They play roles in regulation of cell physiology, 
tumorigenesis, apoptosis, proliferation, invasion, metastasis, and chemoresistance. Many 
miRNAs found in serum have been suggested as reliable biomarkers of early SPC detection 
[61]. Combining several miRNAs with CA19–9 in a composite panel could improve diagnosis 
compared to a single biomarker. This was documented with six miRNAs (including miR-20a, 
miR-21, miR-25, miR-155, miR-196a, and miR-210), and CA19–9 [62]. The panels had a high 
specificity for pancreatic cancer compared to other gastrointestinal cancers and they showed 
better sensitivity and specificity than CA19–9 alone. A panel of miRNAs could be used to dif-
ferentiate patients with new-onset diabetes with SPC, healthy controls, and new-onset Type 
2 diabetes without SPC [63, 64]. MiRNAs were also analyzed using weighted gene co-expres-
sion network analysis (WGCNA). This method better discriminates between healthy and can-
cer patients and demonstrates that miRNAs can serve as prognostic biomarkers [65]. On the 
other hand, a set of 15 selected miRNAs was able to discriminate SPC patients from controls 
at the time of diagnosis but could not be used in earlier stages because their alterations only 
appeared in the later stages of the disease [66].
Another area of investigation provides new data from metabolomic studies that are based 
on metabolic differences between new-onset diabetes with and without pancreatic cancer as 
well as in comparison with Type 2 diabetes [67]. Sixty-two metabolites, from several hundred, 
were analyzed using liquid chromatography/mass spectrometry. The results were able to dis-
criminate between the three abovementioned groups, although the procedure is not yet suit-
able for routine use. In another study, using a metabolomic profile of 206 metabolites, most 
significant changes were found in oleanolic acid, palmitic acid, taurochenodeoxycholate, and 
d-sphingosine, discriminating between healthy controls and pancreatic cancer patients [68].
T3cDM caused by pancreatic cancer is characterized by abnormal concentrations of several 
hormones which participate in glucose homeostasis. In cases where basal plasma concen-
trations of the hormone are within normal limits, the impairment may be disclosed after 
mixed-nutrient stimulation [52]. The determination of insulin, pancreatic polypeptide (PP), 
or glucose-dependent insulinotropic peptide (GIP) during the “meal test” may confirm their 
decreased levels, which would demonstrate their altered dynamics [19].
Exosomes bring new possibilities to the detection of SPC [69]. The proteins, miRNAs, and 
mRNAs transferred by these vesicles originating in cancer cells can be used as biomarkers. 
Several body fluids like serum, urine, and saliva were demonstrated to contain pancreatic 
cancer-derived exosomes [70]. Exosomes may improve early diagnosis of pancreatic can-
cer in stage I and IIA when the tumor is still localized [71]. Two miRNAs, miR-196a and 
miR-1246, were found to be highly enriched in pancreatic cancer exosomes and elevated in 
plasma exosomes of patients with localized pancreatic cancer. Exosomes can be examined 
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in pancreatic juice when new-onset diabetes is suspected as a paraneoplastic symptom of 
SPC [72]. Exosomes trafficking within pancreatic juice may facilitate the development of a 
pre-metastatic niche well before any symptomology that might support an early diagnosis of 
pancreatic cancer [72].
It appears that an early diagnosis is increasingly dependent on a combination of biomarkers 
with sufficient sensitivity to disclose localized tumors or, better still, their precursors.
6.2. Imaging methods
Diagnosis based on visualization of the tumor and classification of its stage is necessary 
for clinical decisions regarding treatment and the use of high-resolution imaging methods 
(HRIMs) is therefore immediately recommended in patients suspected of having SPC. The 
results of different methods were compared using a large database [73]. Effective screening 
procedures for early detection of pancreatic cancer were described by Hanada et al. [74, 75]. 
A review of the advances in various imaging methods, as well as their proper selection is 
beyond the scope of this review.
7. Risk groups of diabetic patients suggested for screening of 
sporadic pancreatic cancer
Early diagnosis and subsequent successful treatment of SPC associated with diabetes depends 
on proper evaluation of the risk groups of patients >50 years of age:
1. Patients with new-onset prediabetes or diabetes:
a. With decreasing body weight (>2 kg) and anorexia as the only clinical symptom
b. With failure of introductory antidiabetic drug therapy during the first 3 months and 
stagnation or a decrease in body weight (>2 kg)
c. With persistent impairment of glucose homeostasis despite the additional of a second 
antidiabetic drug during the next 3 months or a decrease in body weight (>2 kg)
2. Patients with long-term diabetes and obesity when there is a failure of antidiabetic drug 
therapy that developed during the preceding 6 months combined with a decreasing body 
weight (>2 kg).
In patients from the first group, the new-onset diabetes and the loss of body weight may be 
early symptoms of SPC. In the second group, long-term diabetes and obesity are risk  factors 
for SPC [76]. A decline in diabetes control, as measured by glycated hemoglobin HbA1c, may 
precede clinical detection of pancreatic cancer by several months up to 5 years [77]. The fail-
ure of the antidiabetic drug treatment characterized by either poor or worsening diabetes 
control is a common feature of both T3c and T2 diabetic patients with pancreatic cancer [21]. 
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Sometimes the fluctuations of blood glucose confirm unstable diabetes regardless of intensi-
fied insulin treatment. The findings of (1) worsening diabetes control and (2) failure of anti-
diabetic drug treatment indicate the need for SPC screening. Patients in both risk groups (i.e., 
new-onset and long-term diabetes) should be examined according to the structured protocol 
we described earlier [2].
8. Protocol for early sporadic pancreatic cancer detection
The program of early SPC detection has three steps [2]:
a. A clinical suspicion of SPC in the risk groups evaluated by general practitioners (GPs) or 
diabetologists,
b. A determination of biomarkers (oncomarkers, microRNAs, etc.) and hormones (GIP, PP, 
GLP-1) after nutritional stimulation as prescribed by a gastroenterologist,
c. An endoscopic examination of the patient and use of high-resolution imaging methods 
(HRIMs) as prescribed by an endoscopist/radiologist in collaboration with a pathologist.
A multidisciplinary team approach should improve the prognosis of this malignant disease. 
The early symptoms (new-onset T3cDM and weight loss), the effect of the initial antidiabetic 
drug therapy, as well as the failure of antidiabetic therapy in long-term diabetes control, with 
newly developing weight loss, should be properly evaluated by a GP or a diabetologist.
We suggested an algorithm for the examination of patients with new-onset diabetes (Figure 1) 
[2]. Regular screening of blood glucose in the general population above 50 years of age may dis-
close abnormalities in glucose homeostasis. Additionally, the evaluation of body weight and 
any changes during the months prior to the visit is critical. A decrease in body weight > 2 kg 
in a patient with newly confirmed prediabetes or diabetes should arouse suspicion of its para-
neoplastic origin. In this case, a gastroenterologist should be consulted.
A patient with new-onset diabetes should be treated with the first line antidiabetic drug 
according to the guidelines for Type 2 diabetes. If the diabetes control is not satisfactory 
during the first 3 months and body weight remains stable or increases, then a second anti-
diabetic drug should be added. An inadequate response to intensified treatment or uninten-
tional weight loss should lead to a suspicion of T3cDM. In this situation, the collaboration 
with a gastroenterologist, preferably in a tertiary center, is necessary. The patient should be 
tested for PP and GIP secretion after nutritional stimulation. A response by PP and GIP that is 
diminished or absent confirms the pancreatogenic origin of the diabetes (T3cDM). A gastro-
enterologist should arrange the next steps involving an endoscopic examination and HRIMs.
A patient with long-term diabetes with failing antidiabetic drug treatment combined with 
decreasing body weight should be included in the same multistep screening program as 
described for T3cDM patients.
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9. Conclusion
The association of SPC with diabetes mellitus offers an opportunity for early detection 
of this malignant disease. While long-term Type 2 diabetes is an important risk factor of 
SPC, new-onset T3cDM represents an early symptom as well as a pathogenetic feature 
of SPC. Thus, proper assessment of new-onset diabetes with a focus on the analysis of 
early symptoms, that is, failure of antidiabetic drug treatment including unstable diabetes 
requiring insulin administration, represents a promising step in shifting the diagnosis of 
SPC to an earlier stage. New biomarkers and high-resolution imaging methods may help 
discriminate between different pathologies with better accuracy, including identification 
Figure 1. Differential approach to a patient with new onset diabetes/prediabetes. Unintentional weight loss, anorexia or 
no improvement in glucose control with appropriate treatment should prompt an evaluation by a gastroenterologist. 
OAD, oral antidiabetics; EUS, endoscopic ultrasonography; GP, general practitioner.
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of the earlier stages of pancreatic cancer. A multistep and multidisciplinary preventive 
program based on collaboration between GPs, diabetologists and gastroenterologists offers 
an opportunity for timely SPC diagnosis. This approach may improve the prognosis for 
these patients.
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